Literature DB >> 19028999

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

Joannes F M Jacobs1, Albert J Idema, Kalijn F Bol, Stefan Nierkens, Oliver M Grauer, Pieter Wesseling, J André Grotenhuis, Peter M Hoogerbrugge, I Jolanda M de Vries, Gosse J Adema.   

Abstract

The brain is a specialized immune site representing a unique tumor microenvironment. The availability of fresh brain tumor material for ex vivo analysis is often limited because large parts of many brain tumors are resected using ultrasonic aspiration. We analyzed ultrasonic tumor aspirates as a biosource to study immune suppressive mechanisms in 83 human brain tumors. Lymphocyte infiltrates in brain tumor tissues and ultrasonic aspirates were comparable with respect to lymphocyte content and viability. Applying ultrasonic aspirates, we detected massive infiltration of CD4+FoxP3+CD25(high) CD127(low) regulatory T cells (Tregs) in glioblastomas (n = 29) and metastatic brain tumors (n = 20). No Treg accumulation was observed in benign tumors such as meningiomas (n = 10) and pituitary adenomas (n = 5). A significant Treg increase in blood was seen only in patients with metastatic brain tumors. Tregs in high-grade tumors exhibited an activated phenotype as indicated by decreased proliferation and elevated CTLA-4 and FoxP3 expression relative to blood Tregs. Functional analysis showed that the tumor-derived Tregs efficiently suppressed cytokine secretion and proliferation of autologous intratumoral lymphocytes. Most tumor-infiltrating Tregs were localized in close proximity to effector T cells, as visualized by immunohistochemistry. Furthermore, 61% of the malignant brain tumors expressed programmed death ligand-1 (PD-L1), while the inhibitory PD-1 receptor was expressed on CD4+ effector cells present in 26% of tumors. In conclusion, using ultrasonic tumor aspirates as a biosource we identified Tregs and the PD-L1/PD-1 pathway as immune suppressive mechanisms in malignant but not benign human brain tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028999      PMCID: PMC2743219          DOI: 10.1215/15228517-2008-104

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  48 in total

Review 1.  Toll-like receptors on regulatory T cells: expanding immune regulation.

Authors:  Roger P M Sutmuller; Mary E Morgan; Mihai G Netea; Oliver Grauer; Gosse J Adema
Journal:  Trends Immunol       Date:  2006-06-30       Impact factor: 16.687

Review 2.  Natural regulatory T cells: mechanisms of suppression.

Authors:  Makoto Miyara; Shimon Sakaguchi
Journal:  Trends Mol Med       Date:  2007-01-24       Impact factor: 11.951

3.  Foxp3-dependent programme of regulatory T-cell differentiation.

Authors:  Marc A Gavin; Jeffrey P Rasmussen; Jason D Fontenot; Valeria Vasta; Vincent C Manganiello; Joseph A Beavo; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

Review 4.  CD4 regulatory T cells in human cancer pathogenesis.

Authors:  Keith L Knutson; Mary L Disis; Lupe G Salazar
Journal:  Cancer Immunol Immunother       Date:  2006-07-04       Impact factor: 6.968

5.  Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.

Authors:  Smita Nair; David Boczkowski; Martin Fassnacht; David Pisetsky; Eli Gilboa
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 6.  Regulatory T cells and innate immune regulation in tumor immunity.

Authors:  Rong-Fu Wang
Journal:  Springer Semin Immunopathol       Date:  2006-07-13

7.  Transient regulatory T-cells: a state attained by all activated human T-cells.

Authors:  Vinodh Pillai; Sterling B Ortega; C K Wang; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2006-12-19       Impact factor: 3.969

8.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

9.  What is immune privilege (not)?

Authors:  Ian Galea; Ingo Bechmann; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

Review 10.  The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology.

Authors:  David M Sansom; Lucy S K Walker
Journal:  Immunol Rev       Date:  2006-08       Impact factor: 12.988

View more
  97 in total

Review 1.  Targeted Therapies for the Treatment of Glioblastoma in Adults.

Authors:  Ding Fang Chuang; Xuling Lin
Journal:  Curr Oncol Rep       Date:  2019-05-17       Impact factor: 5.075

Review 2.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 3.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

4.  Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

Authors:  Kyu Sang Lee; Kyoungyul Lee; Sumi Yun; Seyoung Moon; Yujun Park; Jung Ho Han; Chae-Yong Kim; Hye Seung Lee; Gheeyoung Choe
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

5.  The role of STAT3 activation in modulating the immune microenvironment of GBM.

Authors:  Alfred P See; James E Han; Jillian Phallen; Zev Binder; Gary Gallia; Fan Pan; Dilini Jinasena; Christopher Jackson; Zineb Belcaid; Sung Jin Jeong; Chelsea Gottschalk; Jing Zeng; Jacob Ruzevick; Sarah Nicholas; Young Kim; Emilia Albesiano; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

6.  The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.

Authors:  Joseph DiDomenico; Jonathan B Lamano; Daniel Oyon; Yuping Li; Dorina Veliceasa; Gurvinder Kaur; Leonel Ampie; Winward Choy; Jason B Lamano; Orin Bloch
Journal:  Oncoimmunology       Date:  2018-04-25       Impact factor: 8.110

7.  RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Authors:  Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai
Journal:  J Neurooncol       Date:  2018-10-23       Impact factor: 4.130

8.  Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Authors:  Reza Mirzaei; Susobhan Sarkar; Lauren Dzikowski; Khalil S Rawji; Lubaba Khan; Andreas Faissner; Pinaki Bose; V Wee Yong
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

9.  Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.

Authors:  Jun Wei; Jason Barr; Ling-Yuan Kong; Yongtao Wang; Adam Wu; Amit K Sharma; Joy Gumin; Verlene Henry; Howard Colman; Waldemar Priebe; Raymond Sawaya; Frederick F Lang; Amy B Heimberger
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

10.  CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Authors:  Daniel Dubinski; Johannes Wölfer; Martin Hasselblatt; Tilman Schneider-Hohendorf; Ulrich Bogdahn; Walter Stummer; Heinz Wiendl; Oliver M Grauer
Journal:  Neuro Oncol       Date:  2015-11-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.